Table 1.
Patient, tumor, and treatment characteristics
| Patient characteristics at time of RT | |
|---|---|
| Age (years) | 68 (42–93) |
| Smoking history | |
| 0–20 pack-years | 1194 (54.0%) |
| >20 pack-years | 469 (21.2%) |
| Unknown | 548 (24.8%) |
| Hypertension | |
| Yes | 959 (43.4%) |
| No | 1252 (56.6%) |
| Hyperlipidemia | |
| Yes | 612 (27.7%) |
| No | 1599 (82.3%) |
| Diabetes mellitus | |
| Yes | 203 (9.2%) |
| No | 2008 (90.8%) |
| Prior cardiovascular event | |
| Yes | 345 (15.6%) |
| No | 1866 (84.4%) |
| Tumor characteristics | |
| AJCC T stage | |
| T1 | 1049 (47.4%) |
| T2 | 937 (42.4%) |
| T3 | 225 (10.2%) |
| Gleason score | |
| ≤ 6 | 1705 (77.1%) |
| 7 | 369 (16.7%) |
| 8–10 | 137 (6.2%) |
| PSA | |
| ≤4 | 289 (13.1%) |
| >4–10 | 1175 (53.1%) |
| >10–20 | 468 (21.2%) |
| >20 | 279 (12.6%) |
| NCCN risk group | |
| Low | 711 (32.2%) |
| Intermediate | 922 (41.7%) |
| High | 578 (26.1%) |
| Treatment characteristics | |
| RT modality | |
| EBRT alone | 1705 (77.1%) |
| Brachytherapy alone | 369 (16.7%) |
| EBRT + brachytherapy | 137 (6.2%) |
| ADT at the time of RT | |
| Yes | 991 (44.8%) |
| No | 1220 (55.2%) |
| Salvage ADT prior to CE | |
| Yes | 365 (16.5%) |
| No | 1846 (83.5%) |
| Time to salvage ADT (years) | 5.5 (0.6 – 18.4) |
ADT, androgen-deprivation therapy; AJCC, American Joint Committee on Cancer; EBRT, external beam radiotherapy; NCCN, National Comprehensive Cancer Network; PSA, prostate-specific antigen; RT, radiotherapy.